| Publications | PubMed=4135597; DOI=10.1093/jnci/53.2.347
Reid T.W., Albert D.M., Rabson A.S., Russell P., Craft J.L., Chu E.W., Tralka T.S., Wilcox J.L.
Characteristics of an established cell line of retinoblastoma.
J. Natl. Cancer Inst. 53:347-360(1974) PubMed=679190
McFall R.C., Nagy R.M., Nagle B.T., McGreevy L.M.
Scanning electron microscopic observation of two retinoblastoma cell lines.
Cancer Res. 38:2827-2835(1978) PubMed=6167750; DOI=10.1093/jnci/67.2.301
Gilbert F., Balaban G.B., Breg W.R., Gallie B.L., Reid T., Nichols W.W.
Homogeneously staining region in a retinoblastoma cell line: relevance to tumor initiation and progression.
J. Natl. Cancer Inst. 67:301-306(1981) PubMed=6351622; DOI=10.1016/S0002-9394(14)77822-5
Ohashi Y., Sasabe T., Nishida T., Nishi Y., Higashi H.
Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells.
Am. J. Ophthalmol. 96:321-325(1983) DOI=10.5795/jjscc.24.451
Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y., Higuchi H., Uei Y.
Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.
Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985) PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=3413073; DOI=10.1073/pnas.85.16.6017
Lee E.Y.-H.P., Bookstein R., Young L.-J., Lin C.-J., Rosenfeld M.G., Lee W.-H.
Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79.
Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988) PubMed=2917337; DOI=10.1016/0165-4608(89)90079-4
Horsthemke B., Greger V., Becher R., Passarge E.
Mechanism of i(6p) formation in retinoblastoma tumor cells.
Cancer Genet. Cytogenet. 37:95-102(1989) PubMed=1679230; DOI=10.3109/13816819109023085
Madreperla S.A., Bookstein R., Jones O.W., Lee W.-H.
Retinoblastoma cell lines Y79, RB355 and WERI-Rb27 are genetically related.
Ophthalmic Paediatr. Genet. 12:49-56(1991) CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992) PubMed=7689221; DOI=10.1073/pnas.90.16.7578
Godbout R., Squire J.A.
Amplification of a DEAD box protein gene in retinoblastoma cell lines.
Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993) PubMed=7499444; DOI=10.1007/BF01213319
Inomata M., Saijo N., Kawashima K., Kaneko A., Fujiwara Y., Kunikane H., Tanaka Y.
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.
J. Cancer Res. Clin. Oncol. 121:729-738(1995) PubMed=18036396; DOI=10.1016/j.cancergencyto.2007.08.014
Paderova J., Orlic-Milacic M., Yoshimoto M., da Cunha Santos G., Gallie B.L., Squire J.A.
Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses.
Cancer Genet. Cytogenet. 179:102-111(2007) PubMed=18799932; DOI=10.1097/MPH.0b013e31816e232d
Kim J.H., Kim J.H., Yu Y.S., Kim D.H., Kim Y.K., Kim K.-W.
Comparative genomic hybridization analysis of newly established retinoblastoma cell lines of adherent growth compared with Y79 of nonadherent growth.
J. Pediatr. Hematol. Oncol. 30:571-574(2008) PubMed=19686387; DOI=10.1111/j.1471-4159.2009.06322.x
Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.
Differential CRX and OTX2 expression in human retina and retinoblastoma.
J. Neurochem. 111:250-263(2009) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010) PubMed=21697133; DOI=10.1167/iovs.11-7479
Oshikawa M., Tsutsui C., Ikegami T., Fuchida Y., Matsubara M., Toyama S., Usami R., Ohtoko K., Kato S.
Full-length transcriptome analysis of human retina-derived cell lines ARPE-19 and Y79 using the vector-capping method.
Invest. Ophthalmol. Vis. Sci. 52:6662-6670(2011) PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7
Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S., Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W., Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K., Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L., Boutros P.C., Lohmann D., Dorsman J.C., Gallie B.L.
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
Lancet Oncol. 14:327-334(2013) PubMed=25326674; DOI=10.1007/s00418-014-1285-z
Busch M., Philippeit C., Weise A., Dunker N.
Re-characterization of established human retinoblastoma cell lines.
Histochem. Cell Biol. 143:325-338(2015) PubMed=27050416; DOI=10.1371/journal.pone.0153011
Ferrario A., Luna M., Rucker N., Wong S., Lederman A., Kim J., Gomer C.
Targeting survivin enhances chemosensitivity in retinoblastoma cells and orthotopic tumors.
PLoS ONE 11:E0153011-E0153011(2016) PubMed=27115612; DOI=10.1371/journal.pone.0153323
Kooi I.E., Mol B.M., Massink M.P., de Jong M.C., de Graaf P., van der Valk P., Meijers-Heijboer H., Kaspers G.J.L., Moll A.C., te Riele H., Cloos J., Dorsman J.C.
A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression.
PLoS ONE 11:E0153323-E0153323(2016) DOI=10.3969/j.issn.1673-713X.2017.04.002
Song W.-P., Zhang C.-Y., Zhang Y., Li Y., Cao R., Ye C., Zhang L., Shao R.-G., Li L., Zhao J.-Y.
Generation of etoposide-resistant subline of human retinoblastoma Y79 cells and preliminary study of its resistance mechanism.
Zhongguo Yiyao Sheng Wu Jishu 12:297-302(2017) PubMed=29162051; DOI=10.1186/s12885-017-3750-2
Nair R.M., Balla M.M.S., Khan I., Kalathur R.K.R., Kondaiah P., Vemuganti G.K.
In vitro characterization of CD133(lo) cancer stem cells in retinoblastoma Y79 cell line.
BMC Cancer 17:779.1-779.12(2017) PubMed=29192327; DOI=10.3892/or.2017.6100
Busch M.A., Papior D., Stephan H., Dunker N.
Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.
Oncol. Rep. 39:160-172(2018) DOI=10.5005/jp-journals-10082-02230
Kuduvalli S.S., Ramalakshmi O., Precilla S.D., Anitha T.S.
Evaluation of cell doubling time in C6 and Y79 cell lines based on seeding density.
SBV J. Basic Clin. Appl. Heatlh Sci. 2:146-149(2019) PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018
Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T., Schramm A., Temming P., Steenpass L.
Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Exp. Cell Res. 375:92-99(2019) PubMed=32123578; DOI=10.1038/s41420-020-0237-8
Aubry A., Yu T., Bremner R.
Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.
Cell Death Discov. 6:2.1-2.12(2020) PubMed=32143590; DOI=10.1186/s12886-020-01348-6
Song W.-P., Zheng S., Yao H.-J., Zhou X.-F., Li R., Zhang C.-Y., Zhao J.-Y., Wang L.-W., Shao R.-G., Li L.
Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism.
BMC Ophthalmol. 20:92.1-92.11(2020) |
|---|
